Metabolic syndrome, insulin resistance and tissue metabolism;Síndrome metabólico, resistencia a la insulina y metabolismo tisular

Endocrinologia y Nutricion

Volumn 50, Issue 8, 2003, Pages 324-333

  Martinez De Morentin B E ^a   Rodriguez M C ^a   Martínez, J Alfredo ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Adipocyte; Insulin resistance; Liver; Metabolic syndrome; Skeletal muscle

Indexed keywords

ACTIVATED PROTEIN C; ADIPONECTIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ADIPOCYTE; ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CAUCASIAN; EUROPE; GLUCOSE HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN METABOLISM; INSULIN RESISTANCE; LIVER; MATHEMATICAL MODEL; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; SKELETAL MUSCLE; TISSUE METABOLISM;

EID: 0242390554     PISSN: 15750922     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1575-0922(03)74546-X     Document Type: Review

References (113)

1. Nilsson S. Research contributions of Eskil Kylin. Sven Med Tidskr 2001;5:15-28.
2. Marañón G. La obesidad desde el punto de vista de su pronóstico y tratamiento. En: Marañón G, editor. Nuevos problemas de las secreciones internas. Madrid: Afrosisio Aguado, 1940; p. 193-231.
3. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
4. Purnell JQ, Brunzell JD. The central role of dietary fat, not carbohydrate, in the insulin resistance syndrome. Curr Opin Lipidol 1997;8:17-22.
5. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993;92:141-46.
6. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995;75:473-86.
7. Reaven GM. Do high carbohydrate diets prevent the development or attenuate the manifestations or both of syndrome X? A viewpoint strongly against. Curr Opin Lipidol 1997;8:23-7.
8. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein and adiponectin. Curr Opin Lipidol 2002;13:51-9.
9. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetes Med 1998;15:539-53.
10. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol In Adults Human (Adult Treatment Panel III). JAMA 2001;285:2486-97.
11. Consenso SEEDO'2000 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Med Clin 2000:15:587-98.
12. Larsson B, Suarsudd K, Welin L, Wilheumsen L, Bjortorp BP, Tibblin G, et al. Abdominal adipose tissue distribution obesity and of cardiovascular disease and death: 13 year follow-up of participants in the study of men born in 1913. Br Med J 1984;288:1401-4.
13. Despres JP, Pascot A, Lemieux J. Risk factors associated with obesity: a metabolic perspective. Ann Endocrinol 2000;6:31-8.
14. Garaulet M, Pérez-Llamas F, Zamora S, Tebar FJ. Interrelationship between serum lipid profile, serum hormones and other components of the metabolic syndrome. J Physiol Biochem 2002;58:151-60.
15. American Association of Clinical Endocrinologists. Code for Dysmetabolic Syndrome X. Disponible en: www.aace.com
16. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilento V. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:1709-2716.
17. Serrano Ríos M. The Metabolic Syndrome in Spain. El síndrome metabólico en su 80 aniversario. Actas 2.° Simposio científico. Madrid, 2002.
18. Grupo de Trabajo Resistencia a la insulina de la Sociedad Española de Diabetes tipo 2. Resistencia a la insulina y su implicación en múltiples factores de riesgo asociados a diabetes tipo 2. Med Clin (Barc) 2002;119:458-63.
19. Himswort HP. Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1936;1:127-34.
20. Rabinowitz D, Zierler KL. Forearm metabolism in obesity and its response to intra-arterial insulin. Evidence for adaptive hyperinsulinismus. Lancet 1961;2:690-2.
21. Reaven GH, Chen YDI. Role of insulin in regulation of lipoprotein metabolism in diabetes. Diab Metabol Rev 1988;4:639-52.
22. De Fronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 199;14:173-94.
23. Brands MW, Hall JE, Keen HL. Is insulin resistance linked to hypertension? Clin Exp Pharmacol Physiol 1998;25:70-6.
24. Yudkin JS, May M, Elwood P, Yarnell JWG, Greenwood R, Davey Smith. Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study. Diabetologia 2002;45:327-36.
25. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:214-23.
26. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol 1979;23:8667-77.
27. Harano Y, Ohgaku S, Hidaka H, Haneda K, Kikkawa R, Shigela Y, et al. Glucose insulin and somatostatin infusions for measurement of in vivo insulin resistance. J Clin Endocrinol Metab 1977;45:1124-27.
28. Bonora E, Moghetti P, Zancanaro C, Cigolini M, Querena M, Cacciarori V, et al. Estimates in vivo insulin action in man: comparation of insulin tolerance test with euglycemic and hyperglicemic glucose clamp studies. J Clin Endocrinol Metab 1989;68:374-8.
29. Matthews DR, Hossker JP, Rudenski AS, Naylor BA, Teacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B cell function from fatting plasma and insulin concentration in man. Diabetologia 1985;28:412-49.
30. Hosker JP, Matthews DR, Rudenski AS, Bumett MA, Darling P, Brorwn EG, et al. Continuous infusion of glucose with model assessment: measurement in insulin resistance and β-cell function in man. Diabetologia 1985;28:401-11.
31. Fernández-Mejía C. Nuevo panorama para el entendimiento de los vínculos moleculares entre la obesidad y la diabetes tipo 2. Rev Invest Clin 2001;53:209-11.
32. Moreno MJ, Martínez JA. El tejido adiposo: órgano de almacenamiento y órgano secretor. Anales Del Sist San Nav 2002:25:29-39.
33. Sniderman AD, Cianflone K, Summers LKM, Fielding BA, Frayn KN. The acylation - stimulating protein pathway and regulation of postprandial metabolism. Nutr Soc 1997;56:703-12.
34. Ong JM, Kern PA. Effect of feeding and obesity on lipoprotein lipase activity, immunoreactive protein, and messenger RNA levels in human adipose tissue. Clin Inves 1989;84:305-11.
35. Coppack SW, Evans RD, Fisher RM, Frayn KN, Gibbons GF, Hockaday TDR, et al. Adipose tissue metabolism in obesity: lipase action in vivo before and after a mixed meal. Metabolism 1992;41:264-72.
36. Flier JS. Diabetes: The missing link with obesity? Nature 2001;409:292-3.
37. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. Journal of Clinical Investigation 1983;72:1737-47.
38. Boden G, Chen X, Ruiz J, White JV y Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994;93:2438-46.
39. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995;44:863-70.
40. Grill V, Qvigstad E. Fatty acids and insulin secretion. Br J Nutr 2000;83:79-84.
41. Old LJ. Tumor necrosis factor (TNF). Science 1985;230:630-32.
42. Bulló Bonet M, García-Lord P, Argilés JM, Salas-Salvadó J. Papel del factor de necrosis tumoral en el control de las reservas grasas y la obesidad. Med Clin (Barc) 2000;114:624-30.
43. Kern PA, Saghidazdeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue: regulation by obesity, weight loss: and relationship to lipoprotein lipase. J Clin Invest 1995;95:2111-19.
44. Saghidazdeh M, Ong J. M, Garvey WT, Henry RR, Kern PA. The expression of TNF-α by human muscle: relationship to insulin resistance. J Clin Invest 1996;97:1111-16.
45. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994;43:1271-8.
46. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF and obesity induced insulin resistance. Science 1996;271:665-8.
47. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF a antibody (CDPS71) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996;45:881-5.
48. Mohamed-Ali V, Goodrick S, Rawesh A, Miles JM, Yudkin JS, Coppack SW, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997;82:4196-200.
49. Koistinen HA, Bastard JP, Dusserre E, Ebeling P, Zegari N, Vidal H, et al. Subcutaneous adipose tissue expression of tumor necrosis factor-alpha is not associated with whole body insulin resistance in obese nondiabetic or in type-2 diabetic subjects. Eur J Clin Invest 2000;30:302-10.
50. Ouchi N, Aichaud G, Negrel R. Novel modulator for endothelial adhesion molecular. Adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-76.
51. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
52. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9.
53. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin. Endocrinol Metab 2001;86:1930-5.
54. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-6.
55. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-53.
56. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-9.
57. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002;13:84-9.
58. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12.
59. Mcternan PG. Increased resistin gene and protein expression in human abdominal adipose tissue. J.Clin Endocrinol Metab 2002;87:2407-10.
60. 3 adrenergic agonist in diet-related overweightness. J Physiol Biochem 2001;57:287-8.
61. Way J M, Gorgun CZ, Tong Q, Uysal K, Brown KK, Harrington WW, et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisoma proliferator - activated receptor gamma agonists. J Biol Chem 2001;276:25651-3.
62. Zhang Y, Proenca R, Maffei N, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse and its human homologue. Nature 1994;372:425-32.
63. Mantzoros C. The role of leptin in human obesity and disease. A review of current evidence. Ann Intern Med 1999;130:671-80.
64. Dagogo-Jack S. Regulation and possible significance of leptin in humans: leptin in health and disease. Diabetes Rev 1999;7:23-37.
65. Wauters M, Considine M, Van Gaal L. Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol 2000;143:293-311.
66. Sinha MK, Opentanova I, Ohannesian JP, Kolaazynsiki JW, Heiman ML, Cano JF. Evidence of free and bound leptin in human circulation: studies in lean and obese subjects and during short term fasting. J Clin Invest 1996;98:1277-82.
67. Haynes W, Sivitz W, Morgan D, Walsh S, Mark A. Sympathetic and cardiorenal actions of leptin. Hypertension 1997;30:619-23.
68. Fruhbeck G. Peripheral actions of leptin and its involvement in disease. Nutr Rev 2002;60:47-55.
69. Lonqvist F, Nordfors L, Schalling M. Leptin and its potential role in human obesity. J Intern Med 1999;245:643-52.
70. Friedman J, Halaas J. Leptin and regulation of body weight in mammals. Nature 1998;395:763-9.
71. Ceddia RB, Koistinen HA, Zierath JR, Sweeney G. Analysis of paradoxical observations on the association between leptin and insulin resistance. FASEB J 2002;16:1163-76.
72. García-Moll X, Kaski JC. Cardiopatía isquémica: marcadores de inflamación y riesgo cardiovascular. Rev Esp Cardiol 1999;52:990-1003.
73. Gotschlich EC. C-reactive protein. A historical overwiew. Ann N Y Acad Sci 1989;557:9-18.
74. Festa A, D'Agostino R, Howard G, Mykkanen L, Russell PT, Haffner S. Chronic subclinical inflammation as part of the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42.
75. Pannacciulli N, Cantatore FP, Minenna A, Bellacicco M, Giorgino R, De Pergola G. C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Int J Obes 2001;2:1416-20.
76. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-Reactive Protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.
77. Person TA, Mensah GA. Markers of inflammation and cardiovascular disease. Circulation 2003;107:499-511.
78. Chmielewska J, Ranby M, Wiman B. Evidence for the occurrence of a fast acting inhibitor for tissue type plasminogen activator in plasma. Thromb Res 1983;31:427-36.
79. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996;2:800-3.
80. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997;46:860-7.
81. Janand-Delenne B, Chagnaud C, Raccah D, Alessi MC, Juhan-Vague I, Vague P. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes 1998:22;312-7.
82. Bastard JP, Pieroni L, Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diab Metab Rev 2000;16:192-201.
83. Orbe J, Martin Trenor A, Rábago G, Belzunce M, Roncal C, Páramo JA. Reducción del potencial fibrinolítico relacionado con aumento de la expresión de PAI-1 vascular en injertos aorto-coronarios. Haematologica (ed. esp.) 2000;85:136.
84. Sridevi Devaraj, Dan Yan Xu, Ishwarlala Jialal. C-reactive Protein Increases Plasminogen Activator Inhibitor-1 expression and Activity in Human Aortic Endothelial Cells. Implications for the Metabolic Syndrome and Atherothombosis. Circulation 2003;107:1-7.
85. Westwater JO, Fainer D. Liver impairment in the obese. Gastroenterology 1958;34:686-93.
86. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-57.
87. Wanless IR, Lentz JS. Fatty liver hepatitis (steathepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 1990;12:1106-10.
88. De Fronzo RA, Ferranini. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hipertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
89. Marchesini G, Brizi M, Morsellio-Labate AH, Bianchi G, Burgianesi E, McCullough AS, et al. Association of nonalcoholic fatty liver disease with insulin resistance: Am J Med 1999;107:450-5.
90. Sanyal AJ, Campbell-Sangert C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-92.
91. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depretis N, et al. Non-alcoholic steatohepatitis, insulin resistance and metabolic syndrome: Further evidence for an etiologic association. Hepatology 2002;35:367-72.
92. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. Nash and insulin resistance: Insulin hypersecretion and specific association with insulin resistance syndrome. Hepatology 2002;35:373-9.
93. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Burgianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
94. Yamashita S, Nakamura T, Shimomura I, Nishida M, Yoshida S, Kotani K, et al. Insulin resistance and body fat distribution. Diabetes Care 1996;19:287-91.
95. Matsuzawa Y, Shimomura I, Nakamura T, Keno Y, Kotani K, Tokunaga K. Pathophysiology and pathogenesis of visceral fat obesity. Obes Res 1995;187-94.
96. Ferrannini E, Camastra S. Relationship between impaired glucose tolerance, non insulin-dependent diabetes mellitus and obesity. Eur J Clin Invest 1998;28:3-6.
97. Bonora E. Relationship between regional fat distribution and insulin resistance. Int Obes 2000;24:32-5.
98. Neuschwander-Tetri BA. A resistance movement in NASH. Am J Gastroenterol 2001;96:2813-4.
99. Wanless IR, Bergman JM, Oreopoulas DG, Vas SI. Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the pathogenesis of steatonecrosis in obesity. Mod Pathol 1989;2:69-74.
100. Sohn J, Siegelman E, Osiason A. Unusual patterns of hepatic steatosis caused by the local effect of insulin revealed on chemical shift MR imaging. Am J Roentgenol 2001;176:471-4.
101. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Medicine 1999;107:450-5.
102. Lee RG. Nonalcoholic steatohepatitis: A study of 39 patients. Hum Pathol 1989;20:594-8.
103. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80.
104. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodoru I, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-23.
105. Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996;62:1802-5.
106. Torres SH. Obesity, insulin resistance and skeletal muscle characteristics. Acta Cient Venez 1999;50:34-41.
107. Sherpherd P, Kahn B. Glucose transporters and insulin action. Implications for insulin resistance and diabetes mellitus. New Engl J Med 1999;341:248-57.
108. Randle PJ. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diab Metabol Rev 1998;14:263-83.
109. Wolfe R. Metabolic interactions between glucose and fatty acids in human. Am J Clin Nutr 1998;67:519-26.
110. Kelley DE, Goodpaster BH, Storlien L. Muscle trigliceride and insulin resistance. Annu Rev Nutr 2002;22:325-46.
111. Kelley DE. Skeletal muscle triglyceride. An aspect of regional adipocity and insulin resistance. Ann N Y Acad Sci 2002;967:135-45.
112. Divisova J, Kazdova L, Hudova M, Meschisvili E. Relationship between insulin resistance and muscle triglyceride content in non-obese experimental models of insulin resistance syndrome. Ann N Y Acad Sci 2002;967:440-5.
113. Kelley DE, Goodpaster BH. Skeletal muscle triglyceride: an aspect of regional adiposity and insulin resistance. Diabetes Care 2001;24:933-41.